temozolomide

Experimental validation using the MTT assay on U87 glioblastoma cells demonstrated that compound 1h exhibited potent cytotoxicity (IC₅₀ = 16.57 ± 0.90μM), significantly outperforming temozolomide. Overall, this study presents the first integrated green-synthetic and computational-experimental evaluation of DHQs against U87 cells, highlighting compound 1h as a promising lead for glioblastoma drug discovery.

P2, N=75, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting

In the NEN cell lines BON-1, QGP-1, and MS-18, we applied cisplatin, etoposide, streptozotocin, 5-fluorouracil, temozolomide, and everolimus- all systemic agents used in highly proliferative NEN. These findings might have an impact on the optimal therapy sequence and patient selection for future CXCR4-targeted approaches. Further, the decreased CXCR4 expression could represent a new mechanism of action of the established drugs Cisplatin, Temozolomide, and Everolimus.

Using a GLICO (GLioblastoma Cerebral Organoid) model, we show that MEOX2 knockdown impairs tumor growth and increases sensitivity to temozolomide (TMZ)...Consistent with this, MEOX2-depleted cells exhibit reduced PARylation levels and increased sensitivity to the PARP1 inhibitor Talazoparib, highlighting a potential therapeutic vulnerability. Altogether, our findings reveal a previously unrecognized role for MEOX2 in the DNA damage response of GSCs, particularly in promoting survival and recovery after chemotherapy and ionizing radiation. These results also suggest that MEOX2 functions as a partner of PARP1 and may represent a promising therapeutic target in GBM.

P=N/A, N=24, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine

P=N/A, N=30, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University

P=N/A, N=90, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P=N/A, N=144, Recruiting, The First Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army; The First Affiliated Hospital of Army Medical Univer

P=N/A, N=60, Not yet recruiting, Cancer Hospital of Shandong First Medical University; Cancer Hospital of Shandong First Medical University

P2, N=27, Not yet recruiting, The Second Affiliated hospital of Fujian Medical University; The Second Affiliated hospital of Fujian Medical University

P2, N=29, Recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital

P2, N=20, Recruiting, Fujian Provincial Tumor Hospital; Fujian Provincial Tumor Hospital